Visit this page to explore and stay updated on the latest advances and practical insights in tumor model-based oncology drug development.
Results:
As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn More
Alfa Cytology delivers one-stop RDC drug-development services, covering target validation, conjugation chemistry, analytical profiling, and preclinical research under a unified workflow.
Learn More
Alfa Cytology delivers end-to-end antibody-radionuclide conjugate development, integrating chelator selection, site-specific labeling, and stability optimization within a unified workflow.
Downloads
At Alfa Cytology, we offer a comprehensive suite of preclinical services tailored to advance cancer research and drug development. Our one-stop preclinical platform provides end-to-end solutions, from disease modeling and diagnostic development to therapeutic evaluation - all under one roof.
Learn More
Single B cell technology has emerged as a powerful method for discovering and developing antibodies, particularly in the context of cancers like bladder cancer.
Learn More
The landscape in cancer immunotherapy has undergone profound changes since its early beginnings up through the rapid advances happening today. The current drug development pipeline consists of thousands of cancer immunotherapies and therapy combinations, many of which are being evaluated in clinical trials.
Learn More
The United Science Group successfully hosted the 2024 International Conference on Cancer Research and Development (Cancer R&D 2024) from November 18-20, bringing together nearly a thousand attendees to explore major advances in cancer research.
Learn More
CRO are specialized entities that offer research services on a contractual basis to innovators. CRO can provide essential drug development services; and also provide expertise in data management, regulatory affairs, and quality assurance.
Learn More
From target discovery to IND application, we provide our clients with up-to-date research findings and actionable insights in different areas of cancer.
Learn More
Alfa Cytology provides highly customizable cancer modeling services that allows our services to be tailored to meet the specific needs of our clients.
Learn More
At Alfa Cytology, the project management (PM) team provides support for preclinical project design and research progress management. The optimized study strategy will accelerate the study timeline and expedite drug development.
Learn More
Alfa Cytology's mission is to provide our clients with the latest research findings and actionable insights in different areas of cancer.
Learn More
Alfa Cytology has established a strong track record in the development of innovative inhibitors against diverse cancer targets. Our team of seasoned researchers and drug discovery experts is dedicated to uncovering novel therapeutic strategies that disrupt the fundamental processes driving cancer growth, progression, and metastasis.
Learn More
Alfa Cytology, a research solutions provider, focused on cancer therapeutic development and preclinical studies. From the complex phases of target discovery to IND application, we offer a seamless experience.
Learn More
X-Drug Conjugates (XDC) are designed to precisely deliver therapeutic agents to diseased cells by linking targeting molecules to potent payloads, reducing off-target effects.
Learn More
Alfa Cytology, a provider of preclinical tumor model services, specializes in CDX, PDX, syngeneic, orthotopic, and humanized models. Supported by a broad portfolio of in vivo platforms and pharmacology expertise, we excel in oncology efficacy evaluation. We offer customized study designs tailored to diverse requirements – your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.
